미국의 펩타이드 치료제(소매) 시장 규모, 점유율, 동향 분석 보고서 : 펩타이드 유형별, 적응증별, 투여 경로별, 치료제 유형별, 유통 채널별, 부문별 예측(2025-2033년)

U.S. Peptide Therapeutics (Retail Side) Market Summary

The U.S. peptide therapeutics (retail side) market size was estimated at USD 103.66 billion in 2024 and is expected to reach USD 336.12 billion by 2033, growing at a CAGR of 12.77% from 2025 to 2033. The increasing number of pediatric patients affected by these conditions, coupled with their widespread occurrence in low-income regions, highlights the need for affordable and effective treatment options. In addition, the increasing number of pediatric patients affected by these conditions, coupled with their widespread occurrence in low-income regions, underscores the need for affordable and effective treatment options.

U.S. Peptide Therapeutics (Retail Side) Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033 For this study, Grand View Research has segmented the U.S. peptide therapeutics (retail side) market report based on peptide type, therapeutics type, indication, route of administration, and distribution channel:

• Peptide Type Outlook (Revenue, USD Billion, 2021 - 2033)
• GLP-1 Peptides
• Wellness/Longevity/Healthspan Peptides
• Peptides for Other Acute or Chronic Medical Conditions
• Therapeutics Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Innovative (Branded) Peptides
• Biosimilar Peptides
• Generic Peptides
• Indication Outlook (Revenue, USD Billion, 2021 - 2033)
• Type 2 Diabetes
• Obesity / Weight Management
• Neuroendocrine Tumors
• Acromegaly
• Growth Hormone Deficiency
• Prostate Cancer
• Osteoporosis
• Breast Cancer (hormone-sensitive)
• Endometriosis
• Others
• Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
• Parenteral
• Oral
• Transdermal
• Nasal
• Others
• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
• Offline Retail Pharmacies
  • Chain pharmacies
  • Specialty retail pharmacies
  • Independent community pharmacies
• Online Pharmacies / Telehealth
• Others (Specialized Peptide Clinics

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment Definitions
• 1.2. Estimates and Forecast Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details of Primary Research
  • 1.4.6. Research Assumption
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Data Visualization
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. Objectives
  • 1.8.1. Objective - 1
  • 1.8.2. Objective - 2
  • 1.8.3. Objective - 3
• 1.9. List of Secondary Sources
• 1.10. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. U.S. Peptide Therapeutics (Retail Side) Market
  • 2.1.1. Market Snapshot
  • 2.1.2. Segment Snapshot
    • 2.1.2.1. Therapeutics type & indication segment outlook
    • 2.1.2.2. Route of administration & distribution channel segment outlook
  • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
  • 3.3.2. Market Restraint Analysis
• 3.4. Regulatory Framework
• 3.5. Business Environment Analysis Tools
  • 3.5.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.5.1.1. Supplier power
    • 3.5.1.2. Buyer power
    • 3.5.1.3. Substitution threat
    • 3.5.1.4. Threat of new entrant
    • 3.5.1.5. Competitive rivalry
  • 3.5.2. PESTEL Analysis
• 3.6. Pricing Analysis in Online vs. Offline Channels
• 3.7. Consumer Awareness Trends for Peptide Therapies
• 3.8. Direct-to-Consumer (DTC) Business Models Impact

Chapter 4. Peptide Type Business Analysis

• 4.1. U.S. Peptide Therapeutics (Retail Side) Market: Peptide Type Movement Analysis
• 4.2. U.S. Peptide Therapeutics (Retail Side) Market: Peptide Type Segment Dashboard
• 4.3. Peptide Type Movement & Market Share Analysis, 2024 & 2033
• 4.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Peptide Type
• 4.5. GLP-1 Peptides
  • 4.5.1. GLP-1 Peptides Market, 2021 - 2033 (USD Million)
• 4.6. Wellness/Longevity/Healthspan Peptides
  • 4.6.1. Wellness/Longevity/Healthspan Peptides Market, 2021 - 2033 (USD Million)
• 4.7. Peptides for Other Acute or Chronic Medical Conditions
  • 4.7.1. Peptides for Other Acute or Chronic Medical Conditions Market, 2021 - 2033 (USD Million)

Chapter 5. Therapeutics Type Business Analysis

• 5.1. U.S. Peptide Therapeutics (Retail Side) Market: Therapeutics Type Movement Analysis
• 5.2. U.S. Peptide Therapeutics (Retail Side) Market: Therapeutics Type Segment Dashboard
• 5.3. Therapeutics Type Movement & Market Share Analysis, 2024 & 2033
• 5.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Therapeutics Type
• 5.5. Innovative (Branded) Peptides
  • 5.5.1. Innovative (Branded) Peptides Market, 2021 - 2033 (USD Million)
• 5.6. Biosimilar Peptides
  • 5.6.1. Biosimilar Peptides Market, 2021 - 2033 (USD Million)
• 5.7. Generic Peptides
  • 5.7.1. Generic Peptides Market, 2021 - 2033 (USD Million)

Chapter 6. Indication Business Analysis

• 6.1. U.S. Peptide Therapeutics (Retail Side) Market: Indication Movement Analysis
• 6.2. U.S. Peptide Therapeutics (Retail Side) Market: Indication Segment Dashboard
• 6.3. Indication Movement & Market Share Analysis, 2024 & 2033
• 6.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Indication
• 6.5. Type 2 Diabetes
  • 6.5.1. Type 2 Diabetes Market, 2021 - 2033 (USD Million)
• 6.6. Obesity / Weight Management
  • 6.6.1. Obesity / Weight Management Market, 2021 - 2033 (USD Million)
• 6.7. Neuroendocrine Tumors
  • 6.7.1. Neuroendocrine Tumors Market, 2021 - 2033 (USD Million)
• 6.8. Acromegaly
  • 6.8.1. Acromegaly Market, 2021 - 2033 (USD Million)
• 6.9. Growth Hormone Deficiency
  • 6.9.1. Growth Hormone Deficiency Market, 2021 - 2033 (USD Million)
• 6.10. Prostate Cancer
  • 6.10.1. Prostate Cancer Market, 2021 - 2033 (USD Million)
• 6.11. Osteoporosis
  • 6.11.1. Osteoporosis Market, 2021 - 2033 (USD Million)
• 6.12. Breast Cancer (hormone-sensitive)
  • 6.12.1. Breast Cancer (hormone-sensitive) Market, 2021 - 2033 (USD Million)
• 6.13. Endometriosis
  • 6.13.1. Endometriosis Market, 2021 - 2033 (USD Million)
• 6.14. Others
  • 6.14.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Route of Administration Business Analysis

• 7.1. U.S. Peptide Therapeutics (Retail Side) Market: Route of Administration Movement Analysis
• 7.2. U.S. Peptide Therapeutics (Retail Side) Market: Route of Administration Segment Dashboard
• 7.3. Route of Administration Movement & Market Share Analysis, 2024 & 2033
• 7.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Route of Administration
• 7.5. Oral
  • 7.5.1. Oral Market, 2021 - 2033 (USD Million)
• 7.6. Parenteral
  • 7.6.1. Parenteral Market, 2021 - 2033 (USD Million)
• 7.7. Transdermal
  • 7.7.1. Transdermal Market, 2021 - 2033 (USD Million)
• 7.8. Nasal
  • 7.8.1. Nasal Market, 2021 - 2033 (USD Million)
• 7.9. Other Route of Administration
  • 7.9.1. Other Route of Administration Market, 2021 - 2033 (USD Million)

Chapter 8. Distribution Channel Business Analysis

• 8.1. U.S. Peptide Therapeutics (Retail Side) Market: Distribution Channel Movement Analysis
• 8.2. U.S. Peptide Therapeutics (Retail Side) Market: Distribution Channel Segment Dashboard
• 8.3. Distribution Channel Movement & Market Share Analysis, 2024 & 2033
• 8.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Distribution Channel
• 8.5. Offline Retail Pharmacies
  • 8.5.1. Offline Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 8.5.2. Chain Pharmacies
    • 8.5.2.1. Chain Pharmacies Market, 2021 - 2033 (USD Million)
  • 8.5.3. Specialty Retail Pharmacies
    • 8.5.3.1. Specialty Retail Pharmacies market, 2021 - 2033 (USD Million)
  • 8.5.4. Independent Community Pharmacies
    • 8.5.4.1. Specialty Market, 2021 - 2033 (USD Million)
• 8.6. Online Pharmacies / Telehealth
  • 8.6.1. Online Pharmacies / Telehealth Market, 2021 - 2033 (USD Million)
• 8.7. Others (Specialized Peptide Clinics)
  • 8.7.1. Others (Specialized Peptide Clinics) Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization (Offline Pharmacies)
• 9.2. Company Categorization (Online Pharmacies)
• 9.3. Company Categorization (Specialized Hormone Clinics)
• 9.4. Participant's Overview
  • 9.4.1. Offline Pharmacies
  • 9.4.2. Online Pharmacies
  • 9.4.3. Specialized Hormone Clinics
• 9.5. Company Market Position Analysis
• 9.6. Strategy Mapping
  • 9.6.1. Regional Expansion
  • 9.6.2. Mergers & Acquisitions
  • 9.6.3. Others
• 9.7. Company Profiles/Listing
• 9.8. Offline Pharmacies
  • 9.8.1. CVS Health
    • 9.8.1.1. Overview
    • 9.8.1.2. Financial performance
    • 9.8.1.3. Product benchmarking
    • 9.8.1.4. Strategic initiatives
  • 9.8.2. Walgreens Boots Alliance, Inc.
    • 9.8.2.1. Overview
    • 9.8.2.2. Financial performance
    • 9.8.2.3. Product benchmarking
    • 9.8.2.4. Strategic initiatives
  • 9.8.3. Walmart Pharmacy
    • 9.8.3.1. Overview
    • 9.8.3.2. Financial performance
    • 9.8.3.3. Product benchmarking
    • 9.8.3.4. Strategic initiatives
  • 9.8.4. Rite Aid Corp
    • 9.8.4.1. Overview
    • 9.8.4.2. Financial performance
    • 9.8.4.3. Product benchmarking
    • 9.8.4.4. Strategic initiatives
  • 9.8.5. The Kroger Co.
    • 9.8.5.1. Overview
    • 9.8.5.2. Financial performance
    • 9.8.5.3. Product benchmarking
    • 9.8.5.4. Strategic initiatives
  • 9.8.6. Albertsons
    • 9.8.6.1. Overview
    • 9.8.6.2. Financial performance
    • 9.8.6.3. Product benchmarking
    • 9.8.6.4. Strategic initiatives
  • 9.8.7. Publix
    • 9.8.7.1. Overview
    • 9.8.7.2. Financial performance
    • 9.8.7.3. Product benchmarking
    • 9.8.7.4. Strategic initiatives
  • 9.8.8. Costco Wholesale Corporation
    • 9.8.8.1. Overview
    • 9.8.8.2. Financial performance
    • 9.8.8.3. Product benchmarking
    • 9.8.8.4. Strategic initiatives
  • 9.8.9. Meijer, Inc.
    • 9.8.9.1. Overview
    • 9.8.9.2. Financial performance
    • 9.8.9.3. Product benchmarking
    • 9.8.9.4. Strategic initiatives
• 9.9. Online Pharmacies
  • 9.9.1. Hims & Hers Health, Inc
    • 9.9.1.1. Overview
    • 9.9.1.2. Financial performance
    • 9.9.1.3. Product benchmarking
    • 9.9.1.4. Strategic initiatives
  • 9.9.2. Ro (Roman Health Ventures Inc.)
    • 9.9.2.1. Overview
    • 9.9.2.2. Financial performance
    • 9.9.2.3. Product benchmarking
    • 9.9.2.4. Strategic initiatives
  • 9.9.3. Lemonaid Health, Inc.
    • 9.9.3.1. Overview
    • 9.9.3.2. Financial performance
    • 9.9.3.3. Product benchmarking
    • 9.9.3.4. Strategic initiatives
  • 9.9.4. Mark Cuban Cost Plus Drug Company, PBC
    • 9.9.4.1. Overview
    • 9.9.4.2. Financial performance
    • 9.9.4.3. Product benchmarking
    • 9.9.4.4. Strategic initiatives
  • 9.9.5. Amazon.com, Inc.
    • 9.9.5.1. Overview
    • 9.9.5.2. Financial performance
    • 9.9.5.3. Product benchmarking
    • 9.9.5.4. Strategic initiatives
  • 9.9.6. Blink Health Administration LLC, Inc.
    • 9.9.6.1. Overview
    • 9.9.6.2. Financial performance
    • 9.9.6.3. Product benchmarking
    • 9.9.6.4. Strategic initiatives
  • 9.9.7. GoodRx, Inc
    • 9.9.7.1. Overview
    • 9.9.7.2. Financial performance
    • 9.9.7.3. Product benchmarking
    • 9.9.7.4. Strategic initiatives
  • 9.9.8. Honeybee Health Inc.
    • 9.9.8.1. Overview
    • 9.9.8.2. Financial performance
    • 9.9.8.3. Product benchmarking
    • 9.9.8.4. Strategic initiatives
  • 9.9.9. TruePill (acquired by LetsGetChecked in October 2024)
    • 9.9.9.1. Overview
    • 9.9.9.2. Financial performance
    • 9.9.9.3. Product benchmarking
    • 9.9.9.4. Strategic initiatives
  • 9.9.10. AgelessRx
    • 9.9.10.1. Overview
    • 9.9.10.2. Financial performance
    • 9.9.10.3. Product benchmarking
    • 9.9.10.4. Strategic initiatives
• 9.10. Specialized Hormone Clinics
  • 9.10.1. Defy Medical
    • 9.10.1.1. Overview
    • 9.10.1.2. Financial performance
    • 9.10.1.3. Product benchmarking
    • 9.10.1.4. Strategic initiatives
  • 9.10.2. Renew Vitality
    • 9.10.2.1. Overview
    • 9.10.2.2. Financial performance
    • 9.10.2.3. Product benchmarking
    • 9.10.2.4. Strategic initiatives
  • 9.10.3. Victory Men's Health
    • 9.10.3.1. Overview
    • 9.10.3.2. Financial performance
    • 9.10.3.3. Product benchmarking
    • 9.10.3.4. Strategic initiatives
  • 9.10.4. Hone Health
    • 9.10.4.1. Overview
    • 9.10.4.2. Financial performance
    • 9.10.4.3. Product benchmarking
    • 9.10.4.4. Strategic initiatives
  • 9.10.5. Joi & Blokes
    • 9.10.5.1. Overview
    • 9.10.5.2. Financial performance
    • 9.10.5.3. Product benchmarking
    • 9.10.5.4. Strategic initiatives
  • 9.10.6. Ways2Well
    • 9.10.6.1. Overview
    • 9.10.6.2. Financial performance
    • 9.10.6.3. Product benchmarking
    • 9.10.6.4. Strategic initiatives
  • 9.10.7. 4Ever Young Anti-aging Solutions
    • 9.10.7.1. Overview
    • 9.10.7.2. Financial performance
    • 9.10.7.3. Product benchmarking
    • 9.10.7.4. Strategic initiatives
  • 9.10.8. T CLINICS USA
    • 9.10.8.1. Overview
    • 9.10.8.2. Financial performance
    • 9.10.8.3. Product benchmarking
    • 9.10.8.4. Strategic initiatives